Bank of China Securities released a research report on April 11 stating that Kangchen Pharmaceutical (603590.SH) was given a purchase rating. The main reasons for the rating include: 1) the profit-side growth rate is impressive, and “Su Ling” continues to expand; 2) the R&D progress of innovative drugs is progressing in an orderly manner, and the company is showing a trend of innovation and transformation; 3) broadening the market for key products and accelerating the R&D process. (Mainichi Keizai Shimbun)
中银证券4月11日发布研报称，给予康辰药业（603590.SH）买入评级。评级理由主要包括：1）利润端增速亮眼，“苏灵”持续放量；2）创新药研发进度有序推进，公司呈创新转型趋势；3）拓宽重点产品市场，加速推进研发进程。（每日经济新闻）
Bank of China Securities released a research report on April 11 stating that Kangchen Pharmaceutical (603590.SH) was given a purchase rating. The main reasons for the rating include: 1) the profit-side growth rate is impressive, and “Su Ling” continues to
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated